Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Genetics,Oncology
Reference131 articles.
1. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N. Engl. J. Med.,2007
2. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N. Engl. J. Med.,2007
4. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J. Clin. Oncol.,2010
5. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer;Thomas;Nat. Med.,2006
Cited by 86 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cell–cell communication: new insights and clinical implications;Signal Transduction and Targeted Therapy;2024-08-07
2. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells;International Journal of Molecular Sciences;2024-06-07
3. Data-driven energy landscape reveals critical genes in cancer progression;npj Systems Biology and Applications;2024-03-08
4. Clinical Importance of Cannabinoid Type 1 Receptor (CB1R) and Cannabinoid Type 2 Receptor (CB2R) Expression in Renal Cell Carcinoma;Cureus;2024-02-28
5. The influence of sex hormones on renal cell carcinoma;Therapeutic Advances in Medical Oncology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3